Health Policies

All Items

• Multicriteria and economic evaluations: toward a proposal for a new framework for drug pricing in Italy

  Andrea Marcellusi, Aldo Pietro Maggioni, Anna Lisa Mandorino, Francesca Caprari, Irene Marzona, Claudio Jommi

  49-54

  DOI: https://doi.org/10.33393/grhta.2026.3604

• The evolution of dialogue and relations between AIFA, clinicians, scientific societies, patient associations, and civic activism organizations

  Alessandra Bianchi, Federica Piccolo, Elisabetta Iannelli, Maria Cristina Carena, Giuliano Buzzetti, Giovanna Scroccaro, Carmine Pinto

  33-37

  DOI: https://doi.org/10.33393/grhta.2026.3643

• Cooperation among stakeholders for the sustainability of the new pharmaceutical paradigm in Italy

  Valentina Drago, Eugenio Di Brino, Roberta Laurita, Filippo Rumi, Michele Basile, Andrea Pierini, Anna Ponzianelli, Francesca Patarnello, Paola Ianna, Filippo Drago

  24-32

  DOI: https://doi.org/10.33393/grhta.2026.3675

• Erratum in: Exploring the administrative burden faced by hematologists: a comprehensive study in Italy

  Davide Petruzzelli, Marco Vignetti, Stefania Trasarti, Paolo Sportoletti, Silvia Della Torre, Roberto Cairoli, Francesca Pia Chiara Leone, Giuseppe Pompilio, Marco Gullì, Eva Brown Hajdukova, Davide Integlia

  22

  DOI: https://doi.org/10.33393/grhta.2026.3725

• Planning and allocating resources for pharmaceuticals to health care organisations: a proposal from the Regional Pharmaceutical Policies Forum

  Claudio Jommi, Barbara Rebesco, Francesco Perrone, Rosy Amodeo, Alberto Bortolami

  265-270

  DOI: https://doi.org/10.33393/grhta.2025.3598

• From Regulatory framework to practice: the EU HTA Regulation 2021/2282, AIFA role and interactions with developers: processes, interfaces, expectations

  Patrizia Popoli, Walter Marrocco, Anna Ponzianelli, Francesco Damele, Massimo Medaglia

  245-248

  DOI: https://doi.org/10.33393/grhta.2025.3599

• Patient and public involvement in health technology assessment committees: who is free from conflicts of interest?

  Gustavo H Marin, Santiago Hasdeu

  242-244

  DOI: https://doi.org/10.33393/grhta.2025.3623

• Spending caps for pharmaceuticals within the pharmaceutical policies framework: critical issues and reform options

  Claudio Jommi

  214-217

  DOI: https://doi.org/10.33393/grhta.2025.3622

• Paving the road for a successful EU HTA Reform implementation

  Hans Severens, Andrew Dillon, Francois Meyer, Claudio Jommi, Iga Lipska, Pier-Luigi Canonico, Oriol Solà-Morales, Herbert Altmann

  194-197

  DOI: https://doi.org/10.33393/grhta.2025.3502

• Real-World Evidence and Managed Entry Agreements

  Silvia Adami, Cosetta Bianchi, Elisa Crovato, Gianluca Trifirò

  163-167

  DOI: https://doi.org/10.33393/grhta.2025.3563

• C(nn) and compassionate use: two approaches for early access. Proposals for a better management

  Alberto Bortolami, Irene Marzona, Paolo Stella, Valentina Acciai, Vito Ladisa, Massimo Medaglia

  158-162

  DOI: https://doi.org/10.33393/grhta.2025.3464

• Healthcare of patients with immunoglobulin A nephropathy through a retrospective observational study of Italian administrative data

  Luigi Biancone, Gaetano La Manna, Letizia Dondi, Leonardo Dondi, Giulia Ronconi, Silvia Calabria, Irene Dell'Anno, Carlo Piccinni, Immacolata Esposito, Alice Addesi, Nello Martini

  130-140

  DOI: https://doi.org/10.33393/grhta.2025.3397

• Regional tools for the governance of prescribing behaviour and pharmaceutical spending: from literature to concrete experiences and prospects for change

  Giovanna Scroccaro , Luca Piccoli , Giacomo Vitturi, Maria Cristina Carena, Gianfranco Valenzano

  98-105

  DOI: https://doi.org/10.33393/grhta.2025.3324

• Management and utilization of the Fund for Innovative Medicines: a multistakeholder qualitative survey on regional and local practices

  Andrea Vitagliano, Marzia Bonfanti, Chiara Lucchetti, Andrea Marcellusi

  89-97

  DOI: https://doi.org/10.33393/grhta.2025.3433

• D.I.Ri.M.O. project: deprescription, inappropriateness evaluation and therapeutic reconciliation in hospital medicine

  Maria Giulia Pollice, Luca Degli Esposti, Cataldo Procacci, Salvatore Lenti, Domenica Ancona, Carmela Nappi, Biagio Iacolare, Anna Maria Tesse, Domenico Leuci, Mara Masullo, Domenico Tricarico

  61-69

  DOI: https://doi.org/10.33393/grhta.2025.3194

• Optimization in the HIV treatment: economic and organizational impact analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide

  Lucrezia Ferrario, Barbara Menzaghi, Giuliano Rizzardini, Alessandro Roccia, Elisabetta Garagiola, Daniele Bellavia, Fabrizio Schettini, Emanuela Foglia

  49-60

  DOI: https://doi.org/10.33393/grhta.2025.3292

• Assessment and value of drugs: report of the focus groups from the XXII National Conference on Pharmaceuticals

  Valentina Drago, Tiziana Mele, Francesca Patarnello, Francesca Randon, Cristina Teruzzi, Filippo Drago

  43-48

  DOI: https://doi.org/10.33393/grhta.2025.3469

• The length of price&reimbursement negotiation procedures in Italy in the period 2021-2023 was independent from the price of medicines

  Raffaella Cocciolo, Paola Turella, Daniela Pilunni, Pierluigi Navarra

  1-6

  DOI: https://doi.org/10.33393/grhta.2025.3259

• Policy predictive model for better management of chronic obstructive pulmonary disease: economic-organisational implications in the Italian healthcare system

  Debora Antonini, Fausto De Michele, Claudio Micheletto, Dejan Radovanovic, Michele Basile, Eugenio Di Brino, Agostino Fortunato, Valentina Donati, Filippo Rumi

  223-230

  DOI: https://doi.org/10.33393/grhta.2024.3114

• Survival, treatment duration and costs of patients with prostate cancer treated with triptorelin in Italy: a study of administrative databases

  Orazio Caffo, Gaetano Facchini, Luca Degli Esposti, Valentina Acciai, Giorgio Mauri, Paola Mazzanti, Giuseppe Fornarini

  207-213

  DOI: https://doi.org/10.33393/grhta.2024.3055

• Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network

  Daniela Segala, Marco Barbieri, Mariachiara Di Nuzzo, Melissa Benazzi, Aurora Bonazza, Letizia Romanini, Brunella Quarta, Kristian Scolz, Anna Marra, Diana Campioni, Rosario Cultrera

  5-12

  DOI: https://doi.org/10.33393/grhta.2024.3094

• Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overview

  Rosario Cultrera

  1-4

  DOI: https://doi.org/10.33393/grhta.2024.3108

• Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panel

  Claudio Jommi, Francesca Patarnello, Cosetta Bianchi, Giuliano Buzzetti

  169-174

  DOI: https://doi.org/10.33393/grhta.2024.3107

• Cabozantinib use in second or subsequent line of treatment in renal cell carcinoma: an analysis of Italian administrative databases

  Cristian Lolli, Antonio Verde, Luca Degli Esposti, Valentina Acciai, Alessia Brigido, Emanuela Proietti, Sarah Scagliarini

  154-160

  DOI: https://doi.org/10.33393/grhta.2024.2892

• Exploring the administrative burden faced by hematologists: a comprehensive study in Italy

  Davide Petruzzelli, Marco Vignetti, Stefania Trasarti, Paolo Sportoletti, Silvia Della Torre, Roberto Cairoli, Francesca Pia Chiara Leone, Giuseppe Pompilio, Marco Gullì, Eva Brown Hajdukova, Davide Integlia

  161-168

  DOI: https://doi.org/10.33393/grhta.2024.3042